Arguing that the Food and Drug Administration is “culpable” in creating the opioid crisis, a consumer advocacy group and a leading academic — who also chairs an FDA advisory panel — are calling for the agency to impose a moratorium on approving any new or reformulated opioids.

In a Citizen’s Petition filed with the FDA, Public Citizen and Dr. Raeford Brown, a professor of anesthesiology and pediatrics at the University of Kentucky, maintained the agency has displayed “dangerously deficient oversight” and that none of more than two dozen opioids approved between 2009 and 2015 provided benefits that outweighed the risks. Two drugs — Opana ER and Dsuvia — were singled out as examples.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • what are the documented instances of diversion of Dsuvia? Lack of retail distribution almost certainly makes this very rare because it is so much more difficult to obtain.
    As you note, Opana ER was approved in 2006, which is outside of the 2009-2015 timeframe discussed here. And it wasn’t designated “abuse deterrent” because that approval predates FDA guidance on what that would be and how it would be determined. It’s like saying a person didn’t travel by auto before autos were invented.
    Not that facts matter anymore in the Rx opioid conversation (unless they fit the current narrative).

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy